Assay News and Research

RSS

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Targeting SARS-CoV-2 with Chaga mushroom – a natural antiviral compound

A new study examines the potential binding interaction of the beneficial components of Chaga mushroom with that of the SARS-CoV-2 RBD.

24 Oct 2021

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.

24 Oct 2021

UCI study demonstrates the efficiency of wastewater-based epidemiology to monitor SARS-CoV-2

Alternative viral detection methods have been critical in the fight against COVID-19, helping to reduce the burden on our healthcare system.

22 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Replication of SARS-CoV-2 variants in different cell and organ models

In this study, the replication of B.1.1.7 viruses was analyzed in different cell and organ models and dwarf hamsters.

22 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Improving Workflow in Life Science Labs

At Lab Innovations 2021* - Porvair Sciences will showcase its extensive range of consumables and instruments for improving workflow in life science laboratories.

From Chromatrap® - Porvair Sciences Ltd 21 Oct 2021

Children show lower seroconversion rates than adults with mild COVID-19

A new study finds that following mild COVID-19, children are more likely to remain seronegative than adults, irrespective of the viral load or symptom severity.

20 Oct 2021

New research on phagocytosis and SARS-CoV-2's spike protein

A new study showed that convalescent patient plasma and monoclonal anti-spike antibodies were able to induce phagocytosis at high antibody concentrations.

20 Oct 2021

Biomarker predicts severity of SARS-CoV-2 infection in patients

A new study investigates a biomarker to predict the severity of disease in patients infected with SARS-CoV-2.

20 Oct 2021

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

A group of researchers performed a drug repurposing screen on an FDA-approved anti-cancer drug named Mitoxantrone.

20 Oct 2021

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Researchers have been investigating the response of antibodies created against SARS-CoV-2 by the Pfizer-BioNTech six months after vaccination.

20 Oct 2021

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

A new preprint suggests a fruitful approach to develop such drugs based on biochemical and molecular modeling studies of the drug remdesivir.

19 Oct 2021

Many people's T-cells recognize the same components of SARS-CoV-2

A new study published on the bioRxiv* preprint aimed to identify highly immunoprevalent CD8 T-cell epitopes specific to SARS-CoV-2 that are confirmed to be endogenously processed and presented on frequently expressed HLA alleles.

18 Oct 2021

Researchers reveal the mechanism of artificial chromosome formation in C. elegans' embryos

A research team led by Dr Karen Wing Yee YUEN, Associate Professor from the School of Biological Sciences at the University of Hong Kong (HKU), revealed the mechanism of artificial chromosome (AC) formation in the embryos of the model organism Caenorhabditis elegans, a 1-mm long, transparent nematode.

18 Oct 2021

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

A new study recently published on the medRxiv* preprint server demonstrates the use of a serological testing algorithm for identifying disparities in infection rates and vaccine uptake amongst the study population to enable public health interventions.

17 Oct 2021